---
schema_version: "secwatch.filing_event.v1"
accession: "0001701478-26-000014"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:06:27.505815+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Azitra reports FY2025 net loss of $11.0M, cash $2.1M; pipeline advances

## Summary
- Net loss widened to $11.0M in FY2025 from $9.0M in FY2024; R&D $4.8M, G&A $6.2M.
- Cash and equivalents of $2.1M as of Dec 31, 2025; completed $8.5M in financings during the year.
- First patient dosed in Phase 1/2 trial for ATR-04 (EGFRi rash); Fast Track from FDA.
- Topline data expected H2 2026 for ATR-12 (Netherton syndrome) and mid-2026 for ATR-04.
- Positive preclinical data for ATR-01 (ichthyosis vulgaris); IND-enabling studies continue in 2026.

## SEC filing metadata
- accession: 0001701478-26-000014
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/0001701478-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/aztr-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701478-26-000014
- JSON: https://secwatch.observer/filing/0001701478-26-000014.json
- Plain text: https://secwatch.observer/filing/0001701478-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.